Resources Archive - Page 7 of 48

Strategies to Accelerate the Development of Antibody-Drug Conjugates

Antibody-drug conjugates (ADCs) hold great promise as cancer therapeutics, as they combine the precision of monoclonal antibodies with the potency...

Development of Rodent Models for Diabetic Neuropathy

Diabetic neuropathy, a common complication of diabetes, affects approximately 50% of diabetic patients and can lead to a range of...

STZ-Induced Diabetic Retinopathy Models

Diabetic retinopathy is a major contributor to vision loss and blindness in working-age adults with diabetes. Developing animal models that...

Overcoming PARP Inhibitor Resistance in an Olaparib-Induced Model

Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those...

Effects of Incretin-Based Therapies on Metabolic and Muscular Homeostasis

Advances in understanding how the body regulates metabolism, particularly the role of incretin hormones, have directly led to the development...

Native Mass Spectrometry Facilitates Validation of DEL Hits

Hit validation is a crucial step in drug discovery based on DNA-encoded libraries (DEL). Rapid and accurate resynthesis of compounds,...

Discovery of a Novel CD39 Inhibitor by DEL Screening

The ATP-adenosine pathway plays a crucial role in regulating immune responses, including those involved in combating tumors. CD39 is an...

Key Steps in Validating Targeted Protein Degraders

Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have...

OncoWuXi Express: Animal Models of Parkinson’s Disease

Introduction： OncoWuXi Express will continue to keep you informed about updates to our online pharmacology model database (OncoWuXi Database), as...

Knowledge Library